Introduction
============

Nonalcoholic fatty liver disease (NAFLD) may be independently associated with increased cardiovascular risk^[@bib1]--[@bib3])^. However, factors linking NAFLD to cardiovascular disease (CVD) are not well known, although some hepatokines, such as fibroblast growth factors 21 (FGF21), Fetuin-A, and selenoprotein P are involved in liver steatosis and atherosclerosis crosstalk^[@bib4],\ [@bib5])^. Fetuin-B is a member of the cystatin super family of cysteine protease inhibitors, sharing 22% homology with Fetuin-A, which has been associated with risk of CVD or atherosclerosis in a few population- based studies^[@bib6],\ [@bib7])^. Meex RC *et al.* reported that Fetuin-B increased in humans with liver steatosis, impaired insulin action in myotubes and hepatocytes, and caused glucose intolerance in mice^[@bib8])^. We recently found that serum Fetuin-B level was positively correlated with intrahepatic triglyceride (IHTG) content and that elevated serum Fetuin-B was independently associated with increased risk of insulin resistance in Chinese adults^[@bib9])^.

Fetuin-B is encoded by the *FETUB* gene, which is located in the human chromosome 3q27.3 with eight exons. The *FETUB* rs4686434 SNP, an intron variant, is characterized by a A-to-G substitution. We recently found that subjects carrying the minor allele G for *FETUB* rs4686434 had lower levels of serum Fetuin-B and decreased IHTG content than their controls^[@bib10])^. We further found a significant joint effect between *FETUB* rs4686434 and patatin-like phospholipase domain-containing-3 (*PNPLA3*) rs738409, another genetic variant associated with NAFLD in multi-ethnic populations in genome-wide association studies^[@bib11])^, on IHTG content^[@bib10])^. Our findings suggest that the genetic variant on *FETUB* rs4686434 might influence hepatic triglyceride accumulation. Our and others' findings suggest that serum Fetuin-B levels and genetic variants on FETUB rs4686434 might influence hepatic triglyceride accumulation.

Available evidence has documented that both NAFLD and insulin resistance are closely associated with atherosclerosis ^[@bib1],\ [@bib3],\ [@bib12])^, and we previously found that a higher serum Fetuin-B level is associated with NAFLD and increases the risk of insulin resistance. This raises the question of whether serum Fetuin-B is associated with subclinical atherosclerosis independently of traditional CVD risk factors. Also, there is no evidence currently available about the association between genetic variants in the *FETUB* locus and subclinical atherosclerosis.

In the present study, we first aimed to explore the independent association between serum Fetuin-B levels and subclinical atherosclerosis (brachial ankle pulse wave velocity (ba-PWV) and ankle-brachial index (ABI)). We also aimed to explore the independent associations of genetic variants in the *FETUB* locus with ba-PWV and ABI.

Methods
=======

Ethics Statement
----------------

This study was approved by the Human Research Ethics Committee of the First Affiliated Hospital of Xiamen University (Xiamen, China). Written informed consent was obtained from each participant. The study complied with the Declaration of Helsinki.

Participants
------------

Details on study participants have been described previously^[@bib9],\ [@bib10])^. In short, 1,523 community-living healthy adults aged 40 years or older with central obesity (waist circumference greater than 90 cm for men and 80 cm for women) living in Lianqian community, Xiamen, China, were recruited for the baseline examination of our designed cohort study in 2011. Of them, 1,140 subjects who had complete data on clinical, serum Fetuin-B, genetic variants on *FETUB* locus and subclinical atherosclerosis measurements remained for the present analysis (**[Fig. 1](#F1){ref-type="fig"}**).

![Study subjects selection diagram](jat-27-418-g001){#F1}

Face-to-face interviews were conducted to collect socio-demographic status, lifestyle habits, present and previous history of health and medications. Subjects underwent weight, height, and waist circumference measurements using a calibrated scale after removing shoes and heavy clothes. Arterial blood pressure was measured with a mercury sphygmomanometer after sitting for at least 15 minutes. Three readings were taken at 5-min intervals and the mean was recorded.

Anthropometric and Biochemical Measurements
-------------------------------------------

Blood samples were obtained after 12-hour fasting for each subject. Plasma glucose and serum lipid profiles, including triglyceride (TG), total cholesterol (TC), and high-density lipoprotein cholesterol (HDL-C) were determined on a HITACHI 7450 analyzer (HITACHI, Tokyo, Japan). Serum uric acid was measured by the autoanalyzer (COBAS INTEGRA 400 plus, Roche, Basel, Switzerland). Fasting plasma glucose (FPG) concentrations were measured by the hexokinase method, and serum fasting insulin concentrations were measured by electrochemiluminiscence immunoassay (Roche Elecsys Insulin Test, Roche Diagnostics, Mannheim, Germany). Homeostasis model assessment - insulin resistance (HOMA-IR) was calculated using the formula: fasting serum insulin (mU/L) \*FPG (mmol/L)/22.5. Insulin resistance was defined as HOMA-IR ≥ 2.6\*10^−6^mol\*U/L^2^. Serum Fetuin-B concentration was measured using the enzyme-linked immunosorbent assay kits (Abcam, Cambridge, UK). The sensitivity of the assay was 4 ng/ml, and the linear range of the standard was 4 to 50 ng/ml. The intra-assay variation was less than 10%, and the inter-assay variation was less than 12%^[@bib9])^.

Hepatic ultrasonography scanning was performed by an experienced radiologist using GE LOGIQ P5 scanner (GE Healthcare, Milwaukee, USA) with a 4-MHz probe, who was blinded to the subject health status. Hepatic steatosis was diagnosed based on characteristic sonographic features, including hepatorenal echo contrast, liver parenchymal brightness, deep beam attenuation, and vessel blurring^[@bib13])^. The definition of NAFLD was based on hepatic ultrasonography diagnosis of hepatic steatosis without excessive alcohol consumption, viral or autoimmune liver disease.

Selection and Genotyping of Tagging SNPs in FETUB Locus
-------------------------------------------------------

Details on selection and genotyping of tagging SNPs in the FETUB locus have been described previously^[@bib10])^. Briefly, a genomic area on human chromosome 3q27.3, encompassing the *FETUB* gene (17.18 kb, eight exons), as well as 5 and 3 kb of its 5′- and 3′-flanking regions, respectively (based on the International HapMap Project phase III data on the Chinese Han Beijing population (release \#28 August 2010, accessed 24 February 2016)), was screened. Seven HapMap SNPs were present and showed the Hardy- Weinberg equilibrium. We focused on the common SNPs only and found 6 SNPs with minor allele frequencies (MAFs) ≥ 0.05 and were genotyped in ≥ 50% of the HapMap individuals. Based on Tagger analysis using Haploview 4.2 software (<http://hapmap.ncbi.nlm.nih.gov/>), the following four SNPs were selected as tagging SNPs covering all the other common SNPs within the locus with an *r*^2^ \> 0.8 (100% coverage): rs4686434 (A/G), rs3733159 (T/G), rs1047115 (A/C) and rs6785067 (G/A) (**[Supplementary Fig. 1](#F2){ref-type="fig"}**). Three of the four *FETUB* tagging SNPs (rs3733159, rs1047115, and rs6785067) obeyed the Hardy-Weinberg equilibrium (*p* \> 0.05). The MAFs of four tested SNPs ranged from 4.1% to 46.7% (**[Supplementary Table 1](#T4){ref-type="table"}**). Results of the linkage disequilibrium (D′, *r*^2^) showed the observed genetic linkage between the tested SNPs was low or moderate (*r*^2^ range: 0.05--0.45).
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###### Genotypes of FETUB tagging SNPs

  *FETUB* tagging SNPs   Genotype     *N*             MAF(%)   *P* value for HWE test
  ---------------------- ------------ --------------- -------- --------------------------------------
  rs4686434 (A \> G)     AA /AG /GG   665 /436 /39    22.5     0.002[\*](#tf7){ref-type="table-fn"}
  rs3733159 (T \> G)     TT /TG /GG   321 /573 /246   46.7     0.745
  rs1047115 (A \> C)     AA /AC /CC   928 /201 /11    9.8      0.974
  rs6785067 (G \> A)     GG /GA /AA   1050 /87 /3     4.1      0.404

*p* \< 0.05

Abbreviations: HWE, Hardy-Weinberg equilibrium; MAF, Minor allele frequency.

Subclinical Atherosclerosis Measurements
----------------------------------------

Brachial ankle pulse wave velocity (ba-PWV) and ABI, indices of subclinical atherosclerosis in the present study, were determined by an arteriosclerosis detection device, Colin VP-1000 (Model BP203RPE III, Omron Corporation, Japan) after subjects had rested for 10--15 minutes. For ba-PWV measurement, pulse waves were measured with cuffs placed on the right/left upper arm and the right/left ankle simultaneously. Differences in the start times of pulse waves were corrected for distance. ABI was calculated by the higher values of systolic blood pressure (BP) in either dorsalis pedis or posterior tibial arterial divided by the higher brachial systolic BP^[@bib14])^. The higher value of ba-PWV and lower value of ABI in either limb were used for further analysis^[@bib14],\ [@bib15])^.

Statistical Analyses
--------------------

### Power Calculation

Power calculation for association of tested SNPs with high ABI (defined as the third tertile of ABI vs. the first and second tertiles of ABI) was conducted using Quanto (version 1.2.4). Among all of the subjects, 380 were defined as high ABI (the third tertile) and 760 were controls (the first and second tertitles). The significance value of 0.05 (two-sides) and logadditive genetic model were used. Under these assumptions, for *FETUB* rs3733159, of which the minor alleles may show increased likelihoods of high ABI and MAF \> 40%, power was sufficient (power \> 0.8). Power for FETUB rs4686434, of which the minor allele may show decreased likelihoods of high ABI and MAF \> 20%, was approximately sufficient. But powers for rs1047115 and rs6785067 (both MAFs \< 10%) were not sufficient (power \< 0.8).

Skewness and kurtosis tests for normality of serum Fetuin-B level, ba-PWV, and ABI were conducted and found following approximation of normal distribution. Data was presented as the mean ± standard deviation for continuous variable or number and percentage for categorical variable. Differences between subjects (categorized by tertiles of ba-PWV, ABI and genotypes of *FETUB* tagging SNPs) were analyzed using one-way ANOVA for continuous variables and chi-square test for categorical variables. Hardy-Weinberg equilibrium was tested using the chisquare test (one degree of freedom). Linkage disequilibrium (D′, *r*^2^) between the tested SNPs was analyzed using MIDAS v1.0 (<http://www.genes.org.uk/software/midas>)^[@bib16])^.

Associations of the *FETUB* tagging SNPs genotypes with ba-PWV and ABI were evaluated by coding the genotype as subjects with 1 or 2 minor alleles v.s. those with 0 minor alleles. Multivariable linear regression was used to explore the independent associations of serum Fetuin-B and genotypes of *FETUB*, tagging SNPs with ba-PWV and ABI in different models with adjustment for potential confounders. In model 1, age and sex were adjusted for; in model 2, educational levels, smoking and drinking habits, and regular physical exercise plus model 1 were adjusted for; in model 3, waist, TC, HDL-cholesterol, and serum uric acid plus model 2 were adjusted for. In model 4, NAFLD (yes vs. no) was further adjusted simultaneously. In model 5, insulin resistance (yes vs. no) was further adjusted.

In each model, Fetuin-B levels were presented per standard deviation (SD) increase, and genotypes were presented as subjects with 1 or 2 minor alleles v.s. those with 0 minor alleles. Based on screening four non-linked tagging SNPs for *FETUB* locus in parallel, a *p* value of 0.0125 was considered statistically significant according to Bonferroni correction for multiple comparisons within the four *FETUB* tagging SNPs. All statistical analyses were performed using Stata14.0 (StatCorp, College Station, TX).

Results
=======

Characteristics of Subjects Stratified by Tertiles of ba-PWV and ABI
--------------------------------------------------------------------

Among the 1,140 subjects, 802 (70.4%) were women and the mean ages (± SD) were 53.6 (± 6.9) years for all. **[Table 1](#T1){ref-type="table"}** shows the differences of characteristics stratified by tertiles of ba-PWV and ABI. In general, with increasing tertiles of ba-PWV, subjects were more likely to be male, older, and have significantly increased levels of waist, systolic and diastolic BP, triglyceride, TC, serum uric acid, HOMA-IR, and decreased level of HDL-C. Increased tertiles of ba-PWV were also significantly associated with higher prevalence rates of NAFLD (48.8%, 61.5%, and 70.5% for tertiles of 1--3, respectively, *p* \< 0.001), insulin resistance (46.2%, 60.4%, and 71.6% for tertiles of 1--3, respectively, *p* \< 0.001) and serum Fetuin-B (3.85 ± 1.39, 4.09 ± 1.40, and 4.27 ± 1.46 µg/ml, *p* = 0.047). Genotypes of the four tested *FETUB* tagging SNPs were not significantly associated with increasing tertiles of ba-PWV. Increased tertiles of ABI were significantly associated with male gender, old age, ever smoking and drinking, increased levels of systolic and diastolic BP, and serum uric acid. But there was no significant difference of prevalence of NAFLD, serum Fetuin-B level s, or genotypes of tested *FETUB* tagging SNPs among increasing tertiles of ABI.

###### Characteristics of subjects by tertiles of brachial ankle pulse wave velocity and ankle-brachial index

                                                        ba-PWV (cm/s)   ABI                                                                                                                                                     
  ------------------------------------- --------------- --------------- --------------- ------------------------------------------ --------------- ---------------- ---------------- ------------------------------------------ -------
  *N* (%)                               381 (33.4%)     379 (33.3%)     380 (33.3%)                                                423 (37.1%)     372 (32.6%)      345 (30.3%)                                                 
  Female (*n*, %)                       286 (75.1%)     250 (66.0%)     266 (70.0%)     0.023[\*](#tf1){ref-type="table-fn"}       317 (74.9%)     265 (71.2%)      220 (63.8%)      0.003^[†](#tf2){ref-type="table-fn"}^      
  Age (years)                           50.4 ± 6.6      53.7 ± 6.5      56.6 ± 6.5      \< 0.001^[‡](#tf3){ref-type="table-fn"}^   52.2 ± 7.1      53.6 ± 6.9       55.1 ± 6.7       \< 0.001^[‡](#tf3){ref-type="table-fn"}^   
  Education, (*n*, %)                                                                   0.218                                                                                        0.234                                      
      Illiteracy                        98 (25.7%)      100 (26.4%)     123 (32.4%)                                                125 (29.6%)     103 (27.7%)      93 (27.0%)                                                  
      Elementary school                 115 (30.2%)     112 (29.6%)     106 (27.9%)                                                136 (32.2%)     99 (26.6%)       98 (28.4%)                                                  
      Middle school                     78 (20.5%)      95 (25.1%)      86 (22.6%)                                                 85 (20.1%)      83 (22.3%)       91 (26.4%)                                                  
      High school or above              90 (23.6%)      72 (19.0%)      65 (17.1%)                                                 77 (18.2%)      87 (23.3%)       63 (18.2%)                                                  
  Ever smoking (*n*, %)                 93 (24.4%)      110 (29.0%)     84 (22.1%)      0.082                                      93 (22.0%)      86 (23.1%)       108 (31.3%)      0.007^[†](#tf2){ref-type="table-fn"}^      
  Ever drinking (*n*, %)                50 (13.1%)      71 (18.7%)      56 (14.7%)      0.089                                      59 (14.0%)      48 (12.9%)       70 (20.3%)       0.013[\*](#tf1){ref-type="table-fn"}       
  Regular physical exercise (*n*, %)    123 (32.3%)     135 (35.6%)     121 (31.8%)     0.482                                      135 (31.9%)     120 (32.3%)      124 (35.9%)      0.442                                      
  Waist circumference (cm)              92.6 ± 7.4      94.3 ± 7.7      93.5 ± 6.1      0.005^[†](#tf2){ref-type="table-fn"}^      93.2 ± 7.6      93.4 ± 6.9       93.8 ± 6.7       0.525                                      
  Systolic blood pressure (mmHg)        121.4 ± 11.7    133.2 ± 13.1    146.4 ± 17.5    \< 0.001^[‡](#tf3){ref-type="table-fn"}^   130.9 ± 16.6    134.1 ± 18.1     136.6 ± 17.8     \< 0.001^[‡](#tf3){ref-type="table-fn"}^   
  Diastolic blood pressure (mmHg)       73.2 ± 8.5      80.3 ± 8.9      84.8 ± 11.2     \< 0.001^[‡](#tf3){ref-type="table-fn"}^   78.1 ± 10.4     80.0 ± 10.8      80.5 ± 11.0      0.006^[†](#tf2){ref-type="table-fn"}^      
  Triglyceride (mmol/L)                 1.55 ± 1.03     1.99 ± 1.32     2.17 ± 1.43     \< 0.001^[‡](#tf3){ref-type="table-fn"}^   1.96 ± 1.39     1.79 ± 1.17      1.95 ± 1.30      0.132                                      
  Total cholesterol (mmol/L)            5.69 ± 1.04     5.95 ± 1.04     6.07 ± 1.13     \< 0.001^[‡](#tf3){ref-type="table-fn"}^   5.92 ± 1.10     5.88 ± 1.05      5.91 ± 1.09      0.849                                      
  HDL-cholesterol (mmol/L)              1.41 ± 0.30     1.36 ± 0.28     1.35 ± 0.29     0.016[\*](#tf1){ref-type="table-fn"}       1.38 ± 0.31     1.37 ± 0.27      1.37 ± 0.30      0.876                                      
  Serum uric acid (⊠mol/L)              349.0 ± 95.9    372.8 ± 90.0    370.1 ± 95.1    \< 0.001^[‡](#tf3){ref-type="table-fn"}^   354.5 ± 91.9    364.7 ± 89.8     374.7 ± 100.6    0.012[\*](#tf1){ref-type="table-fn"}       
  HOMA-IR (\* 10^−6^mol\* IU\* L^−2^)   2.84 ± 1.65     3.67 ± 3.22     4.09 ± 2.82     \< 0.001^[‡](#tf3){ref-type="table-fn"}^   3.69 ± 2.74     3.34 ± 1.91      3.56 ± 3.28      0.184                                      
  Insulin resistance (*n*, %)           176 (46.2%)     229 (60.4%)     272 (71.6%)     \< 0.001^[‡](#tf3){ref-type="table-fn"}^   266 (62.9%)     218 (58.6%)      193 (55.9%)      0.140                                      
  NAFLD (*n*, %)                        186 (48.8%)     233 (61.5%)     268 (70.5%)     \< 0.001^[‡](#tf3){ref-type="table-fn"}^   265 (62.7%)     222 (59.7%)      200 (58.0%)      0.404                                      
  Serum Fetuin-B (µg/ml)                3.85 ± 1.39     4.09 ± 1.40     4.27 ± 1.46     0.047[\*](#tf1){ref-type="table-fn"}       4.19 ± 1.39     4.18 ± 1.45      4.06 ± 1.31      0.365                                      
  *FETUB* Genotypes                                                                                                                                                                                                             
      rs4686434                         AG/GG           162 (42.5%)     159 (42.0%)     154 (40.5%)                                0.848           162 (38.3%)      168 (45.2%)      145 (42.0%)                                0.145
                                        AA              219 (57.5%)     220 (58.1%)     226 (59.5%)                                                261 (61.7%)      204 (54.8%)      200 (58.0%)                                
      rs3733159                         TG/GG           267 (70.1%)     271 (71.5%)     281 (74.0%)                                0.487           304 (71.9%)      276 (74.2%)      239 (69.3%)                                0.343
                                        TT              114 (29.9%)     108 (28.5%)     99 (26.0%)                                                 119 (28.1%)      96 (25.8%)       106 (30.7%)                                
      rs1047115                         AC/CC           80 (21.0%)      62 (16.4%)      70 (18.4%)                                 0.258           85 (20.1%)       66 (17.7%)       61 (17.7%)                                 0.607
                                        AA              301 (79.0%)     317 (83.6%)     310 (81.6%)                                                338 (79.9%)      306 (82.3%)      284 (82.3%)                                
      rs6785067                         GA/AA           30 (7.9%)       29 (7.7%)       31 (8.2%)                                  0.967           38 (9.0%)        29 (7.8%)        23 (6.7%)                                  0.494
                                        GG              351 (92.1%)     350 (92.4%)     349 (91.8%)                                                385 (91.0%)      343 (92.2%)      322 (93.3%)                                

*p* \< 0.05

*p* \< 0.01

*p* \< 0.001

All percentages are column percentage;

Abbreviations: ABI, Ankle-brachial index; ba-PWV, brachial ankle pulse wave velocity; HDL, high-density lipoprotein; NAFLD, non-alcoholic fatty liver disease

Differences of ba-PWV and ABI Stratified by Genotypes of FETUB Tagging SNPs
---------------------------------------------------------------------------

**[Table 2](#T2){ref-type="table"}** shows that all genotypes of the *FETUB* tagging SNPs were not significantly associated with levels of ba-PWV or ABI.

###### Differences of brachial ankle pulse wave velocity and ankle-brachial index by genotypes of FETUB tagging SNPs

                  FETUB tagging SNPs                                                              
  --------------- -------------------- ---------------- ------- ---------------- ---------------- -------
  ba-PWV (cm/s)   1529.2 ± 295.6       1517.9 ± 299.7   0.529   1515.9 ± 317.8   1527.8 ± 288.9   0.546
  ABI             1.07 ± 0.07          1.08 ± 0.08      0.663   1.07 ± 0.08      1.07 ± 0.07      0.809

                  FETUB tagging SNPs                                                              
  --------------- -------------------- ---------------- ------- ---------------- ---------------- -------
  ba-PWV (cm/s)   1528.3 ± 298.2       1507.7 ± 292.8   0.364   1525.0 ± 297.4   1518.4 ± 296.5   0.839
  ABI             1.07 ± 0.07          1.07 ± 0.08      0.459   1.07 ± 0.07      1.07 ± 0.08      0.890

*p* \< 0.0125

Abbreviations: ABI, Ankle-brachial index; ba-PWV, brachial ankle pulse wave velocity; IHTG, intrahepatic triglyceride; NAFLD, non-alcoholic fatty liver disease.

Associations of Serum Fetuin-B and FETUB SNPs with ba-PWV and ABI
-----------------------------------------------------------------

Based on the multivariable linear regression analyses with adjustment for potential confounding factors in different models, **[Table 3](#T3){ref-type="table"}** shows the (standardized) regression coefficients (*β*) of serum Fetuin-B and genotypes of the tested *FETUB* tagging SNPs on ba-PWV and ABI. With adjustment for sex and age in model 1, higher serum Fetuin-B was significantly associated with increased ba-PWV, and the standardized *β* of per SD increase of serum Fetuin-B was 0.075 (*p* = 0.008). With additional adjustments for educational levels, ever smoking, ever drinking and regular physical exercise habits in model 2, and further adjustment for waist, TC, HDL-cholesterol, and serum uric acid in model 3, the standardized *β* of per SD increase of serum Fetuin-B for ba-PWV were 0.071 (*p* = 0.011) and 0.057 (*p* = 0.039), respectively. Even with further adjustment for NAFLD in model 4, both NAFLD and serum Fetuin-B level were still significantly associated with increased ba-PWV (the standardized *β*: 0.127 and 0.055, respectively; both *p*-values \< 0.05). All genotypes of the4 *FETUB* tagging SNPs were not significantly associated with ba-PWV in all of the different models. In model 5, with further adjustment for insulin resistance, plus model 4, both NAFLD and insulin resistance were significantly and positively associated with ba-PWV (the standardized *β*: 0.086 and 0.183, respectively; both *p*-values \< 0.05), however the association between serum Fetuin-B and ba-PWV was not significant (the standardized *β*: 0.047, *p* = 0.086).

###### Multivariable linear regression of serum Fetuin-B and genotypes of *FETUB* tagging SNPs on brachial ankle pulse wave velocity and ankle-brachial index

                                                   ba-PWV (cm/s)              ABI                                                                                         
  ------------------------------------------------ -------------------------- -------- -------- ----------------------------------------- ---------- --------- ---------- --------------------------------------
                                                   All Sample (*N* = 1,140)                                                                                               
  Model 1                                                                                                                                                                 
  Serum Fetuin-B^[†](#tf6){ref-type="table-fn"}^   22.359                     8.349    0.075    0.008[\*](#tf5){ref-type="table-fn"}      −0.00027   0.00225   −0.00365   0.903
  FETUB genotypes                                                                                                                                                         
      rs4686434 (AG/GG v.s. AA)                    −11.586                    16.488   −0.019   0.482                                     0.00149    0.00442   0.00978    0.736
      rs3733159 (TG/GG v.s. TT)                    14.517                     18.049   0.022    0.421                                     0.00175    0.00484   0.01047    0.718
      rs1047115 (AC/CC v.s. AA)                    −16.344                    20.915   −0.021   0.435                                     −0.00297   0.00561   −0.01538   0.597
      rs6785067 (GA/AA v.s. GG)                    1.851                      30.111   0.002    0.951                                     −0.00011   0.00807   −0.00038   0.990
  Model 2                                                                                                                                                                 
  Serum Fetuin-B^[†](#tf6){ref-type="table-fn"}^   21.250                     8.309    0.071    0.011[\*](#tf5){ref-type="table-fn"}      −0.00029   0.00225   −0.00383   0.898
  FETUB genotypes                                                                                                                                                         
      rs4686434 (AG/GG v.s. AA)                    −11.032                    16.406   −0.018   0.501                                     0.00157    0.00443   0.01032    0.723
      rs3733159 (TG/GG v.s. TT)                    9.354                      17.996   0.014    0.603                                     0.00178    0.00486   0.01067    0.714
      rs1047115 (AC/CC v.s. AA)                    −16.817                    20.796   −0.022   0.419                                     −0.00301   0.00562   −0.01562   0.592
      rs6785067 (GA/AA v.s. GG)                    1.529                      29.940   0.001    0.959                                     −0.00020   0.00808   −0.00072   0.980
  Model 3                                                                                                                                                                 
  Serum Fetuin-B^[†](#tf6){ref-type="table-fn"}^   17.050                     8.247    0.057    0.039[\*](#tf5){ref-type="table-fn"}      −0.00018   0.00226   −0.00238   0.937
  FETUB genotypes                                                                                                                                                         
      rs4686434 (AG/GG v.s. AA)                    −13.364                    16.176   −0.022   0.409                                     0.00181    0.00443   0.01191    0.683
      rs3733159 (TG/GG v.s. TT)                    9.977                      17.742   0.015    0.574                                     0.00197    0.00486   0.01182    0.685
      rs1047115 (AC/CC v.s. AA)                    −15.409                    20.517   −0.020   0.453                                     −0.00349   0.00562   −0.01810   0.535
      rs6785067 (GA/AA v.s. GG)                    −3.975                     29.558   −0.004   0.893                                     0.00005    0.00809   0.00018    0.995
  Model 4                                                                                                                                                                 
  NAFLD (yes v.s. no)                              77.304                     17.897   0.127    \< 0.001[\*](#tf5){ref-type="table-fn"}   −0.01394   0.00493   −0.09094   0.005[\*](#tf5){ref-type="table-fn"}
  Serum Fetuin-B^[†](#tf6){ref-type="table-fn"}^   16.291                     8.185    0.055    0.047[\*](#tf5){ref-type="table-fn"}      −0.00004   0.00226   −0.00056   0.985
  FETUB genotypes                                                                                                                                                         
      rs4686434 (AG/GG v.s. AA)                    −13.688                    16.048   −0.023   0.394                                     0.00187    0.00442   0.01229    0.672
      rs3733159 (TG/GG v.s. TT)                    10.053                     17.602   0.015    0.568                                     0.00196    0.00484   0.01174    0.686
      rs1047115 (AC/CC v.s. AA)                    −13.408                    20.362   −0.018   0.510                                     −0.00385   0.00560   −0.01997   0.492
      rs6785067 (GA/AA v.s. GG)                    −0.116                     29.339   −0.001   0.997                                     −0.00064   0.00807   −0.00230   0.937
  Model 5                                                                                                                                                                 
  NAFLD (yes v.s. no)                              52.051                     18.010   0.086    0.004[\*](#tf5){ref-type="table-fn"}      −0.01224   0.00505   −0.07979   0.016[\*](#tf5){ref-type="table-fn"}
  Insulin resistance (yes v.s. no)                 110.714                    17.118   0.183    \< 0.001[\*](#tf5){ref-type="table-fn"}   −0.00749   0.00480   −0.04904   0.119
  Serum Fetuin-B^[†](#tf6){ref-type="table-fn"}^   13.822                     8.050    0.047    0.086                                     0.00013    0.00226   0.00167    0.956
  FETUB genotypes                                                                                                                                                         
      rs4686434 (AG/GG v.s. AA)                    −12.836                    15.759   −0.021   0.416                                     0.00181    0.00441   0.01192    0.681
      rs3733159 (TG/GG v.s. TT)                    15.498                     17.299   0.023    0.371                                     0.00160    0.00485   0.00960    0.741
      rs1047115 (AC/CC v.s. AA)                    −12.436                    19.995   −0.016   0.534                                     −0.00392   0.00560   −0.02031   0.484
      rs6785067 (GA/AA v.s. GG)                    −7.570                     28.830   −0.007   0.793                                     −0.00014   0.00807   −0.00052   0.986

*p* \< 0.05

OR and 95%CI was impressed by per SD increase of serum Fetuin-B.

Model 1 was adjusted for sex and age;

Model 2 was adjusted for educational level, ever smoking, ever drinking and regular physical exercise + model 1;

Model 3 was adjusted for waist, total cholesterol, HDL-cholesterol and serum uric acid + model 2.

Model 4 was adjusted for NAFLD + model 3.

Model 5 was adjusted for insulin resistance + model 4.

Abbreviations: ABI, Ankle-brachial index; ba-PWV, brachial ankle pulse wave velocity; NAFLD, non-alcoholic fatty liver disease.

The multivariable linear regression analyses on ABI showed neither serum Fetuin-B levels nor genotypes of the tested *FETUB* tagging SNPs were significantly associated with ABI with adjustment for potential confounding factors in different models.

Discussion
==========

In the present study of 1,140 community-living Chinese adults with central obesity, we found that increasing tertiles of ba-PWV were significantly associated with higher prevalence of NAFLD and serum Fetuin-B. After adjusting for traditional CVD risk factors, even NAFLD per se, we found serum Fetuin-B level was significantly and positively associated with ba-PWV. But there was no significant association between serum Fetuin-B and ABI. Furthermore, we found all genotypes of the four tested *FETUB* tagging SNPs were not significantly associated with either ba- PWV or ABI.

NAFLD has been consistently associated with metabolic/insulin resistance syndrome and, thus, has been proposed to predict atherosclerosis and CVD^[@bib1],\ [@bib6]--[@bib7])^, but factors linking NAFLD to atherosclerosis and CVD have not been fully understood. Fetuin-B was the second member of the fetuin family, the cystatin superfamily of cysteine protease inhibitor^[@bib17])^. As a new kind of hepatokine, it is of interest to explore the role of Fetuin-B on the association linking NAFLD to atherosclerosis and CVD. Meex and Zhu *et al.* found a significant association between Fetuin-B and liver steatosis^[@bib8],\ [@bib18])^. We recently found that serum Fetuin-B level was independently and positively correlated with intrahepatic triglyceride content^[@bib9])^. In the present study based on the same cohort, we found that, with increasing tertiles of ba-PWV, which is an ideal indicator for assessing subclinical atherosclerosis and is widely used to assess cardiovascular risk in general populations, subjects were more likely to show higher prevalence rate of NAFLD and increased levels of serum Fetuin-B. And the positive association between serum Fetuin-B and ba-PWV sustained statistically significant with adjustment for traditional CVD risk factors in the multivariable linear regression analysis. We are probably the first, to the best of our knowledge, to report the positive association of serum Fetuin-B with ba-PWV. However, ABI, another noninvasive measurement of subclinical atherosclerosis^[@bib14])^, was not significantly associated with serum Fetuin-B in the present study.

Evidence about mechanisms underlying the association between Fetuin-B and atherosclerosis is not available at present. Meex found that Fetuin-B impaired insulin sensitivity in myotubes and hepatocytes, but they found Fetuin-B had no effect on proinflammatory signaling or cytokine release, and they concluded Fetuin-B might induce insulin resistance in a manner quite distinct from that of Fetuin-A^[@bib8])^. Zhu and co-workers reported that serum Fetuin-B increased in subjects with NAFLD^[@bib18])^. We previously found that subjects with the highest levels of serum Fetuin-B showed significantly higher NAFLD prevalence, and the highest IHTC content, and that elevated Fetuin-B level was independently associated with increased risk of insulin resistance^[@bib9])^. Together with the present finding that NAFLD was significantly and positively associated with ba-PWV but the significant association between Fetuin-B and ba-PWV disappeared with further adjustment for insulin resistance, we therefore suspected that Fetuin-B might link NAFLD to atherosclerosis through insulin resistance. But future studies about other mechanisms, such as oxidative stress and endothelial dysfunction besides insulin resistance, through which Fetuin-B induces atherosclerosis should be conducted^[@bib4],\ [@bib19]--[@bib20])^

The *FETUB* gene encodes the protein Fetuin-B. *FETUB* rs4686434 SNP is an intron variant, characterized by a A-to-G substitution. We previously found that *FETUB* rs4686434 G-allele carriage was significantly associated with lower serum Fetuin-B and decreased IHTG content^[@bib10])^. But we did not find any significant association between genotypes of the four tested *FETUB* tagging SNPs and the indicators of subclinical atherosclerosis (ba-PWV and ABI) in the present study. One possible reason for the null association between the tested tagging SNPs, ba-PWV and ABI was due to the small sample size in the present study, therefore, future studies with relatively large sample size are warranted to verify our findings.

Since women had significantly higher serum Fetuin-B levels than men (4.37 ± 1.39 v.s. 3.64 ± 1.24 µg/ml, *p* \< 0.001), we therefore conducted separate analyses for women and men about the independent association of serum Fetuin-B and common genetic variants in *FETUB* locus with ba-PWV and ABI. We actually found similar results (data not shown), but the power has decreased dramatically due to the much smaller sample size for the subgroup analyses.

Causes for the discrepancy that serum Fetuin-B was found to be positively associated with ba-PWV but not with ABI in the present study, were not clearly understood. ABI measurement provides one of the most practical means to assess the presence of atherosclerosis, and ba-PWV, which mainly reflects the left ventricular structure and function, is affected by not only central elastic arteries but also peripheral muscular ones^[@bib21])^. In our previous publication, even in the present study, we both found that, compared to controls, subjects with NAFLD showed significantly increased ba-PWV levels but did not show it significantly decreased ABI^[@bib22])^. It should be noted that all subjects in the present study were all centrally obese with much higher prevalence rates of NAFLD (51.5%) than the general adults, which may prevent us from finding significant association of NAFLD with ba-PWV and ABI in the obese adults.

We should acknowledge the following limitations in the present study. The first major limitation was that our subjects were all centrally obese with a relatively higher prevalence rate of NAFLD. Around 60% of our subjects were diagnosed as NAFLD, and we may, therefore, under-estimate the true associations of serum Fetuin-B with subclinical atherosclerosis (ba-PWV and ABI). Our findings could not be generalized into the common populations, especially for lean subjects. Another major limitation was that our sample size might not have sufficient power to find significant associations between these candidate variants of the *FETUB* locus and the two indicators of subclinical atherosclerosis (ba-PWV and ABI). Therefore, an independent cohort with larger sample size, especially from a prospective cohort study design, should be conducted to validate our findings in future. Third, NAFLD was determined by hepatic ultrasonography scanning, which was considered unreliable and difficult to use in obese subjects^[@bib23])^. Fourth, we cannot preclude the possibility of reverse causality between serum Fetuin-B and atherosclerosis due to our cross-sectional study design. Fifth, although Meex, Zhu and we all found significant association of serum Fetuin-B with liver steatosis^[@bib8],\ [@bib9],\ [@bib18])^, Peter recently found serum Fetuin-B level did not correlate with liver fat content or insulin sensitivity^[@bib24])^, therefore, more studies should be conducted in different populations before the consistent findings between Fetuin-B and liver steatosis has been reached. Sixth, we should acknowledge that although serum Fetuin-B is mainly from liver, it may also be from other organs, as Denecke *et al.* suggested^[@bib25])^. Seventh, ba-PWV and ABI may not be ideal indices for atherosclerosis, especially for those obese subjects. Last but not the least, a few hepatokines, such as FGF-21, Fetuin-A and selenoprotein P^[@bib4],\ [@bib5])^, which have been associated with atherosclerosis and may confound our findings, have not been tested in the present study. But we believed this will not eliminate the association between Fetuin-B and ba-PWV, since we have adjusted for NAFLD per se in the multivariable linear regression analyses.

Conclusions
===========

Factors linking NAFLD to atherosclerosis have not been understood clearly and there is no human study on the association of Fetuin-B with subclinical atherosclerosis. We are probably the first, to the best of our knowledge, to report the significantly positive association of serum Fetuin-B with ba-PWV in the obese Chinese adults. Together with our finding that common genetic variants in the *FETUB* locus were not significantly associated with atherosclerosis indicators, our results may imply that serum Fetuin-B may not be causally associated with ba-PWV but may link NAFLD to atherosclerosis via inducing insulin resistance. Further studies about other mechanisms, such as oxidative stress and endothelial dysfunction, through which Fetuin-B may induce atherosclerosis, should be conducted in future.
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